Sexual activity in implantable cardioverter defibrillator patients included in cardiac rehabilitation

被引:2
|
作者
Maria Maroto-Montero, Jose [1 ,2 ]
Maroto-de Pablo, Marta [2 ,3 ]
Starling-Duarte, Juan [1 ]
Prados-Cabiedas, Carolina [4 ]
Villahoz-Garcia, Carmen [2 ]
Cabrero-Soblechero, Lara [2 ]
Sanchez-Corbal, Marta [1 ]
Valverde-dos Anjos, Belen [1 ]
Munoz-Sanjuan, Yesica [1 ]
机构
[1] Hosp Vithas Nuestra Senora de Fatima, Unidad Rehabil Cardiaca, Vigo, Pontevedra, Spain
[2] Residencia Socio Sanitaria, Unidad Rehabil Cardiaca Ecoplar, Madrid, Spain
[3] Univ Autonoma, Fac Med, Madrid, Spain
[4] Hosp Univ Ramon & Cajal, Serv Cardiol, Unidad Rehabil Cardiaca, Madrid, Spain
来源
ARCHIVOS DE CARDIOLOGIA DE MEXICO | 2018年 / 88卷 / 02期
关键词
Implantable cardioverter defibrillator; Sexual activity; Cardiac rehabilitation; Spain;
D O I
10.1016/j.acmx.2017.07.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To analyse the effects of a Cardiac Rehabilitation Program (CRP) on quality of life and sexual activity levels in patients with implantable cardioverter defibrillators (ICD). Method: A total of 25 patients (22 men and 3 women) were included in a study that consisted of the analysis of any defibrillator discharges, their repercussion on the couple, and the effects of CRP on physical and psychological aspects, and on sexual activity (SA). Results: The mean age of the patients was 55 years (22 to 79). Initially, fear for device discharges was present in all patients. On arrival, 14 patients (56%) did not have any SA: 2 with ages of 69 and 79 years; one woman due to severe anxiety; an alcoholic man, and 10 because the ICD had been implanted less than 1 month before. Nine men and two women had restarted SA: 5 of them 5-52 months after the implantation, and the other 6, 30 days after implantation of the ICD while attending the CRP. At the end of the study, 21 patients had regained SA. Two men had clinical signs of depression and anxiety, with one requiring specialised treatment. Functional capacity improved significantly, 6.5 +/- 3.0 METs at the beginning of the program and 9.2 +/- 3.3 METs at the end, with a P < .005. There was only one inappropriate discharge. Conclusions: Discharges caused by newest devices have dropped significantly. This fact, together with the action of CRP at physical, psychological, and informative levels, makes it possible to control the dysfunctions in the quality of life and sexuality in patients. (C) 2017 Institute Nacional de Cardiologi'a Ignacio Chavez. Published by Masson Doyma Mexico S.A. This is an open access article under the CC BY-NC-ND license.
引用
收藏
页码:116 / 123
页数:8
相关论文
共 50 条
  • [31] Implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis
    Itoh, Mitsuru
    Ohmori, Konosuke
    Yata, Kenichiro
    Wada, Hideho
    Tsuchiya, Tetsuo
    Okahashi, Noriko
    Hamanaka, Sohei
    Yoshida, Kiyoshi
    Tanemoto, Kazuo
    Sugihara, Takashi
    AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (07) : 560 - 561
  • [32] Radiotherapy in patients with cardiac implantable electronic device either a permanent pacemaker or an implantable cardioverter defibrillator
    Yasemin Benderli Cihan
    La radiologia medica, 2017, 122 : 538 - 539
  • [33] The implantable cardioverter defibrillator
    Rinaldi, CA
    Gill, JS
    HOSPITAL MEDICINE, 2002, 63 (11): : 672 - 675
  • [34] THE IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
    FURMAN, S
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1991, 14 (02): : 249 - 249
  • [35] Implantable cardioverter defibrillator and cardiac resynchronization therapy in patients with left ventricular noncompaction
    Kobza, R.
    Steffel, J.
    Erne, P.
    Schoenenberger, A. W.
    Huerlimann, D.
    Luscher, T. F.
    Jenni, R.
    Duru, F.
    EUROPEAN HEART JOURNAL, 2010, 31 : 835 - 835
  • [36] SURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC AMYLOIDOSIS
    Higgins, Angela
    Annapureddy, Amarnath
    Wang, Yongfei
    Minges, Karl
    Lampert, Rachel
    Rosenfeld, Lynda
    Jacoby, Daniel
    Curtis, Jeptha
    Miller, Edward
    Freeman, James
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 694 - 694
  • [37] Implantable cardioverter defibrillator therapy is not associated with survival benefits in patients with cardiac amyloidosis
    Lin, G.
    Mirzoyev, Z.
    Grogan, M.
    Dispenzieri, A.
    Brady, P. A.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2007, 18 : S94 - S94
  • [38] Early benefit of implantable cardioverter defibrillator therapy in patients waiting for cardiac transplantation
    Lorga, A
    Geelen, P
    Vanderheyden, M
    Malacky, T
    Primo, J
    Goethals, M
    Wellens, F
    Brugada, P
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1998, 21 (09): : 1747 - 1750
  • [39] Elevated γ-glutamyltransferase in implantable cardioverter defibrillator patients
    Dichtl, Wolfgang
    Wolber, Thomas
    Paoli, Ursula
    Theurl, Thomas
    Bruellmann, Simon
    Stuehlinger, Markus
    Berger, Thomas
    Spuller, Karin
    Strasak, Alexander
    Pachinger, Otmar
    Haegeli, Laurent
    Duru, Firat
    Hintringer, Florian
    WIENER KLINISCHE WOCHENSCHRIFT, 2012, 124 (1-2) : 18 - 24
  • [40] PHANTOM SHOCKS IN PATIENTS WITH AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
    Juan, Emerson A.
    Pollack, Marc
    JOURNAL OF EMERGENCY MEDICINE, 2010, 38 (01): : 22 - 24